Checkpoint Inhibitor Pneumonitis (CIP) Program

About Lanier Biotherapeutics

Lanier Biotherapeutics is a private, preclinical-stage biotech developing antibody treatments across retinal, inflammatory, dermatological, and immuno-oncology indications. Its lead program targets checkpoint inhibitor pneumonitis (CIP), a serious side effect of cancer immunotherapy, while also pursuing biobetter anti-VEGF therapies for retinal diseases and treatments for type 2 inflammatory conditions. The company is backed by private investors and led by a small team of seasoned executives, positioning itself to address significant unmet medical needs in niche and broad therapeutic areas.

Therapeutic Areas